Reduction in hepatitis B virus seroprevalence among U.S.-born children of foreign-born Asian parents—Benefit of universal infant hepatitis B vaccination

Shuler, Carrie M.; Fiore, Anthony E.; Neeman, Ruth; Bell, Beth P.; Kuhnert, Wendi L.; Watkins, Sandra L.; Kilgour, Kimberly; Arnold, Kathryn E.

doi:10.1016/j.vaccine.2009.07.087

Cited by 16 publications

(6 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since the launch of the first universal hepatitis B vaccination program for infants in July 1984 in Taiwan, infant immunization programs in different countries have resulted in marked reductions in the incidence and prevalence of hepatitis B among younger members of these populations [114][115][116][117]. This has been marked in Arab countries such as Libya, where the prevalence among pregnant women dropped from 2.8% to 2.1% in three years from 2003, and then to 1.5% in 2010, which is likely owing to the effect of vaccination, which has been provided since 2000 [33].…”

Section: Vaccinationmentioning

confidence: 99%

Hepatitis B and C virus infections among pregnant women in Arab and African countries

Gasim

Murad

Adam

2013

J Infect Dev Ctries

View full text Add to dashboard Cite

Introduction: The epidemiology of viral hepatitis during pregnancy is of paramount importance for health planners and program managers. Data on viral hepatitis during pregnancy are not readily available in many African and Arab countries. Both regions have their own unique geography, and comprise over 59 states with crossover and interaction of different cultures. Methodology: A systematic electronic search of the published literature was conducted and data on epidemiology and risk factors of maternal hepatitis B virus (HBV) infection and hepatitis C (HCV) infection in Arab and African countries were extracted from relevant studies. Results: The serology of hepatitis viruses varies greatly among these countries, with different viral genotype patterns. Such a variation in prevalence could be explained by the different risk factors involved. Sexual contact, perinatal infection, blood and its derivatives, hemodialysis, intravenous and percutaneous drug use, and occupational, habitual, and social behavior have been identified as risk factors for hepatitis transmission in various settings in these countries. Conclusions: Infection from hepatitis B and C viruses imposes major socioeconomic and even political burdens on such young and dynamic societies. Thus strategies and clear policies of intervention are required to combat the consequences of hepatitis B and C at both the regional and national levels.

show abstract

Section: Vaccinationmentioning

confidence: 99%

Hepatitis B and C virus infections among pregnant women in Arab and African countries

Gasim

Murad

Adam

2013

J Infect Dev Ctries

View full text Add to dashboard Cite

show abstract

“…Areas such as Taiwan and Thailand, however, have demonstrated that implementation of infant vaccination programs can have profound effects on lowering rates of infection and chronicity (7,8). Nevertheless, in the United States alone, where the majority of states require HBV vaccination prior to enrollment in public schools (38), there are upwards of 2 million chronically infected individuals (12). Thus, there remains a need for continued development and evaluation of HBV vaccination programs and treatment options.…”

mentioning

confidence: 99%

A Vesicular Stomatitis Virus-Based Hepatitis B Virus Vaccine Vector Provides Protection against Challenge in a Single Dose

Cobleigh

Buonocore

Uprichard

et al. 2010

J Virol

View full text Add to dashboard Cite

As one of the world's most common infectious diseases, hepatitis B virus (HBV) is a serious worldwide public health problem, with HBV-associated liver disease accounting for more than half a million deaths each year. Although there is an effective prophylactic vaccine currently available to prevent infection, it has a number of characteristics that are suboptimal: multiple doses are needed to induce long-lasting immunity, immunity declines over time, it does not elicit protection in some individuals, and it is not effective therapeutically. We produced a recombinant vesicular stomatitis virus (VSV)-based vaccine vector expressing the HBV middle envelope surface protein (MS) and found that this vector was able to efficiently generate a strong HBs-specific antibody response following a single immunization in mice. A single immunization with the VSV-MS vector also induced robust CD8 T-cell activation. The CD8 T-cell response was greater in magnitude and broader in specificity than the response generated by a vaccinia virus-based vaccine vector or by recombinant protein immunization. Furthermore, a single VSV-MS immunization provided protection against virus challenge in mice. Given the similar antibody titers and superior T-cell responses elicited from a single immunization, a VSV-based HBV vaccine may have advantages over the current recombinant protein vaccine.

show abstract

“…We defined early diagnosis as diagnosis of infection soon after infection (100% probability of diagnosis for infants who are serologically tested) and late diagnosis as detection of infection at a 1% annual rate, [20][21][22] or when the infection becomes symptomatic. We estimated hepatitis-related costs and QALY loss for early and late diagnosis and for perinatal and childhood infection.…”

Section: Overviewmentioning

confidence: 99%

Cost-effectiveness Analysis of the National Perinatal Hepatitis B Prevention Program

et al. 2014

View full text Add to dashboard Cite

METHODS:A decision analytic tree and a long-term Markov model represented the risk of perinatal and childhood infections under different prevention alternatives, and the long-term health and economic consequences of HepB infection. Outcome measures were the number of perinatal infections and childhood infections from infants born to HepB surface antigen-positive women, quality-adjusted life-years (QALYs), lifetime costs, and incremental cost per QALY gained. The health outcomes and total costs of each strategy were compared incrementally. Costs were evaluated from the health care system perspective and expressed in US dollars at a 2010 price base. RESULTS:In all analyses, the PHBPP increased QALYs and led to higher reductions in the number of perinatal and childhood infections than no PHBPP, with a cost-effectiveness ratio of $2602 per QALY. In sensitivity analyses, the cost-effectiveness ratio was robust to variations in model inputs, and there were instances where the program was both more effective and cost saving.CONCLUSIONS: This study indicated that the current PHBPP represents a cost-effective use of resources, and ensuring the program reaches all pregnant women could present additional public health benefits.

show abstract

Reduction in hepatitis B virus seroprevalence among U.S.-born children of foreign-born Asian parents—Benefit of universal infant hepatitis B vaccination

Cited by 16 publications

References 23 publications

Hepatitis B and C virus infections among pregnant women in Arab and African countries

Hepatitis B and C virus infections among pregnant women in Arab and African countries

A Vesicular Stomatitis Virus-Based Hepatitis B Virus Vaccine Vector Provides Protection against Challenge in a Single Dose

Cost-effectiveness Analysis of the National Perinatal Hepatitis B Prevention Program

Contact Info

Product

Resources

About